期刊文献+

混合型肝癌和胆管癌的临床病理特点及预后分析 被引量:4

Analysis of the Clinicopathologic Characteristics and Prognosis of Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma
下载PDF
导出
摘要 目的:探讨混合型肝癌和胆管癌(combined hepatocellular carcinoma and cholangiocarcinoma,cHCC-CC)的临床病理特点,并分析影响其预后的独立因素。方法:收集2007年1月—2011年12月行手术治疗且术后病理诊断为cHCC-CC的105例患者的临床资料,回顾分析其临床病理特点、诊断和治疗方法,采用Kaplan-Meier法分析cHCC-CC患者术后总体生存率和无瘤生存率,Cox回归模型分析其影响预后的独立因素。结果:105例患者术前均误诊为原发性肝细胞癌(hepatocellular carcinoma,HCC)。患者男女比例为4.5∶1,平均(51.1±9.3)岁。其中乙肝表面抗原阳性93例(88.6%),肝硬化50例(47.6%)。术前,71例(67.6%)甲胎蛋白(AFP)阳性(>20μg/L),6例(5.7%)癌胚抗原(carcinoembryonic antigen,CEA)阳性(>10μg/L),46例(43.8%)糖类抗原19-9(CA19-9)阳性(>39 U/mL)。患者术后1、3、5年的总体生存率和无瘤生存率分别为47.6%、27.7%、27.7%和28.6%、21.4%、11.2%,总体生存率和无瘤生存率的中位生存时间分别为8.8个月和4.2个月。多因素分析结果表明,CEA水平和肿瘤直径是cHCC-CC预后的独立危险因素。结论:cHCC-CC预后较差,CEA阳性和肿瘤直径>3cm是肝切除术后的影响总体生存率的独立危险因素。 Objective:To explore the clinicopathologic characteristics of combined hepatocellular carcinoma and cholangiocarcinoma(cHCC-CC) and to analyze the independent prognostic factors.Methods:Datum from 105 pathologically confirmed cHCC-CC patients who underwent hepatectomy from January 2007 to December 2011 were collected.The clinicopathological characteristics,diagnosis,treatments were retrospectively analyzed.Kaplan-Meier method was used to detect the overall and disease-free survival rate.Cox regression model was used to analyze the independent prognostic factors.Results: All of the 105 cases were misdiagnosed as hepatocellular carcinoma(HCC).Of all the patients,the ratio of male to female was 4.5∶1,with the average age of(51.1±9.3) years,including 93(88.6%) patients with seropositive hepatitis B surface antigen and 50(47.6%) patients with cirrhosis.Before operation,patients with positive α-fetoprotein(AFP)20 μg/L,carcinoembryonic antigen(CEA)10 μg/L and carbohydrate antigen 19-9(CA19-9)39 U/mL were 71(67.6%),6(5.7%) and 46(43.8%),respectively.The 1,3,and 5-year overall and disease-free survival rates were 47.6%,27.7%,27.7% and 28.6%,21.4%,11.2%,respectively.The median survival time for overall and disease-free survival rates were 8.8 months and 4.2 months,respectively.Multivariate analysis results showed that serum level of carcinoembryonic antigen(CEA) and tumor size were the independent prognostic factors of cHCC-CC.Conclusions: The prognosis of cHCC-CC is poor.Elevated serum level of CEA and tumor diameter3 cm are the independent prognostic factors for overall survival rate of cHCC-CC patients after resection.
出处 《中国临床医学》 2013年第3期297-300,共4页 Chinese Journal of Clinical Medicine
关键词 混合型肝癌和胆管癌 临床病理特征 生存率 预后 Combined hepatocellular carcinoma and cholangiocarcinoma Clinicopathologic characteristics Survival rate Prognosis
  • 相关文献

参考文献1

二级参考文献45

  • 1[35]Aishima S,Kuroda Y,Asayama Y,Taguchi K,Nishihara Y,Taketomi A,Tsuneyoshi M.Prognostic impact of cholangiocellular and sarcomatous components in combined hepatocellular and cholangiocarcinoma.Hum Pathol 2006; 37:283-291
  • 2[36]Tanaka S,Yamamoto T,Tanaka H,Kodai S,Ogawa M,Ichikawa T,Hai S,Sakabe K,Uenishi T,Shuto T,Kubo S.Potentiality of combined hepatocellular and intrahepatic cholangiocellular carcinoma originating from a hepatic precursor cell:Immunohistochemical evidence.Hepatol Res 2005; 32:52-57
  • 3[37]Kim H,Park C,Han KH,Choi J,Kim YB,Kim JK,Park YN.Primary liver carcinoma of intermediate (hepatocyte-cholangiocyte) phenotype.J Hepatol 2004; 40:298-304
  • 4[38]Robrechts C,De Vos R,Van den Heuvel M,Van Cutsem E,Van Damme B,Desmet V,Roskams T.Primary liver tumour of intermediate (hepatocyte bile duct cell) phenotype:a progenitor cell tumour? Liver 1998; 18:288-293
  • 5[39]Koh KC,Lee H,Choi MS,Lee JH,Paik SW,Yoo BC,Rhee JC,Cho JW,Park CK,Kim HJ.Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma.Am J Surg 2005; 189:120-125
  • 6[40]Yano Y,Yamamoto J,Kosuge T,Sakamoto Y,Yamasaki S,Shimada K,Ojima H,Sakamoto M,Takayama T,Makuuchi M.Combined hepatocellular and cholangiocarcinoma:a clinicopathologic study of 26 resected cases.Jpn J Clin Oncol 2003; 33:283-287
  • 7[1]Libbrecht L,Roskams T.Hepatic progenitor cells in human liver diseases.Semin Cell Dev Biol 2002; 13:389-396
  • 8[2]Lowes KN,Brennan BA,Yeoh GC,Olynyk JK.Oval cell numbers in human chronic liver diseases are directly related to disease severity.Am J Pathol 1999; 154:537-541
  • 9[3]Libbrecht L,Desmet V,Van Damme B,Roskams T.Deepintralobular extension of human hepatic 'progenitor cells' correlates with parenchymal inflammation in chronic viral hepatitis:can 'progenitor cells' migrate? J Pathol 2000; 192:373-378
  • 10[4]Eleazar JA,Memeo L,Jhang JS,Mansukhani MM,Chin S,Park SM,Lefkowitch JH,Bhagat G.Progenitor cell expansion:an important source of hepatocyte regeneration in chronic hepatitis.J Hepatol 2004; 41:983-991

共引文献23

同被引文献51

  • 1Louis Libbrecht.Hepatic progenitor cells in human liver tumor development[J].World Journal of Gastroenterology,2006,12(39):6261-6265. 被引量:24
  • 2吕文平,董家鸿,李智华,陈平.肝细胞癌手术后应用不同分期评估预后的临床研究[J].中华普通外科杂志,2007,22(7):514-517. 被引量:1
  • 3Yeh MM. Pathology of combined hepatocellular-cholangiocarcinoma [J]. J Gastroenterol Hepatol,2010,25(9):1485.
  • 4Cazals-Hatem D,Rebouissou S,Bioulac-Sage P,et al. Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas [J]. J Hepatol,2004,41(2):292-298.
  • 5Koh KC,Lee H,Choi MS,et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma[J]. Am J Surg,2005,189(1):120-125.
  • 6Tang D,Nagano H,Nakamura M,et al. Clinical and pathological features of Allen’s type C classification of resected combined hepatocellular and cholangiocarcinoma:a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma[J]. J Gastrointest Surg,2006,10(7):987-998.
  • 7Portolani N,Baiocchi GL,Coniglio A,et al. Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma:a Western experience[J]. Ann Surg Oncol,2008,15(7):1880-1890.
  • 8Park SE,Lee SH,Yang JD,et al. Clinicopathological characteristics and prognostic factors in combined hepatocellular carcinoma and cholangiocarcinoma[J]. Korean J Hepatobiliary Pancreat Surg,2013,17(4):152-156.
  • 9Okuda K,Ohtsuki T,Obata H,et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients[J]. Cancer,1985,56(4):918-928.
  • 10Kudo M,Chung H,Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score):its value and limitations,and a proposal for a new staging system,the Japan Integrated Staging Score (JIS score)[J]. J Gastroenterol,2003,38(3):207-215.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部